mdlinx mdlinx
Print

Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response
Journal of Surgical Oncology, 04/26/2012

Facciuto ME et al. – Stereotactic body radiation therapy (SBRT) achieves total or partial radiological response in 37% of patients and total or partial pathological response in 37% of patients with early HCC in the setting of cirrhosis. SBRT may be a safe and effective alternative for local tumor control in patients with HCC and cirrhosis awaiting OLT.

Methods
  • From 2006 to 2009, 27 HCC patients (AJCC I, II) listed for OLT underwent SBRT.
  • Thirty–nine lesions were treated and 27 assessed radiologically.
  • Seventeen patients had OLT, liver explants were analyzed and 22 lesions underwent pathological evaluation.

Results
  • In a cumulative analysis of all imaging, 30% had complete response, 7% had partial response, 56% were stable, and 7% had progression of disease.
  • Of the 22 pathologically evaluated lesions, 37% were responders: 14% with complete response, 23% with partial response, and 63% with no response.
  • Side effects from SBRT were recorded in three patients, which included nausea in two and liver decompensation in one.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close